OBJECTIVE: To examine the association between preadmission statin use and mortality among patients with bacteremia in a population-based setting. DESIGN: Observational study based on prospective registration of bacteremia episodes and mortality over a 6-yr period. SETTING: North Jutland County, Denmark (population, 500,000). PATIENTS: A total of 5,353 adult patients hospitalized with bacteremia from 1997 to 2002. Individuals treated with statins (n = 176) were identified by record-linkage with the County Prescription Database. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: We compared mortality rates 0-30 and 31-180 days after bacteremia in patients with and without preadmission statin use, adjusted for gender, age group, level of comorbidity, alcohol-related conditions, use of immunosuppressive drugs and systemic antibiotics, and focus on infection. The 30-day mortality in statin users vs. nonusers was similar (20.0% vs. 21.6%, adjusted mortality rate ratio 0.93, 95% confidence interval 0.66-1.30). Among survivors after 30 days, however, statin therapy was associated with a substantially decreased mortality up until 180 days after the bacteremia (8.4% vs. 17.5%, adjusted mortality rate ratio 0.44, 95% confidence interval 0.24-0.80). This tendency toward similar short-term and decreased longer term mortality associated with statin use was observed consistently in both community-acquired and nosocomial bacteremia episodes and when analyses were restricted to patients with previous cardiovascular discharge diagnoses or diabetes. CONCLUSIONS: This study provides evidence against the hypothesis that statin use has an effect on short-term mortality after bacteremia. Statin use was, however, associated with a substantially decreased mortality between 31 and 180 days after bacteremia.
OBJECTIVE: To examine the association between preadmission statin use and mortality among patients with bacteremia in a population-based setting. DESIGN: Observational study based on prospective registration of bacteremia episodes and mortality over a 6-yr period. SETTING: North Jutland County, Denmark (population, 500,000). PATIENTS: A total of 5,353 adult patients hospitalized with bacteremia from 1997 to 2002. Individuals treated with statins (n = 176) were identified by record-linkage with the County Prescription Database. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: We compared mortality rates 0-30 and 31-180 days after bacteremia in patients with and without preadmission statin use, adjusted for gender, age group, level of comorbidity, alcohol-related conditions, use of immunosuppressive drugs and systemic antibiotics, and focus on infection. The 30-day mortality in statin users vs. nonusers was similar (20.0% vs. 21.6%, adjusted mortality rate ratio 0.93, 95% confidence interval 0.66-1.30). Among survivors after 30 days, however, statin therapy was associated with a substantially decreased mortality up until 180 days after the bacteremia (8.4% vs. 17.5%, adjusted mortality rate ratio 0.44, 95% confidence interval 0.24-0.80). This tendency toward similar short-term and decreased longer term mortality associated with statin use was observed consistently in both community-acquired and nosocomial bacteremia episodes and when analyses were restricted to patients with previous cardiovascular discharge diagnoses or diabetes. CONCLUSIONS: This study provides evidence against the hypothesis that statin use has an effect on short-term mortality after bacteremia. Statin use was, however, associated with a substantially decreased mortality between 31 and 180 days after bacteremia.
Authors: John P Magulick; Christopher R Frei; Sayed K Ali; Eric M Mortensen; Mary Jo Pugh; Christine U Oramasionwu; Kelly R Daniels; Ishak A Mansi Journal: Am J Med Sci Date: 2014-03 Impact factor: 2.378
Authors: Kelly Lima Calisto; Bruno de Melo Carvalho; Eduardo Rochete Ropelle; Francine Cappa Mittestainer; Angélica Costa Aranha Camacho; Dioze Guadagnini; José Barreto Campelo Carvalheira; Mario José Abdalla Saad Journal: PLoS One Date: 2010-12-06 Impact factor: 3.240
Authors: Kevin B Laupland; Henrik C Schønheyder; Karina J Kennedy; Outi Lyytikäinen; Louis Valiquette; John Galbraith; Peter Collignon; Deirdre L Church; Daniel B Gregson; Pamela Kibsey Journal: BMC Res Notes Date: 2009-07-22